Akebia Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheet
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| (dollars in thousands, except per share amounts) | March 31,2024 | December 31,2023 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $41,961 | $42,925 |
| Inventories | 25,532 | 15,691 |
| Accounts receivable, net | 26,620 | 39,290 |
| Prepaid expenses and other current assets | 18,831 | 20,243 |
| Total current assets | 112,944 | 118,149 |
| Property and equipment, net | 3,265 | 3,629 |
| Operating right-of-use assets | 11,399 | 12,416 |
| Intangible asset, net | 27,032 | 36,042 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 11,793 | 12,423 |
| Total assets | $225,477 | $241,703 |
| Liabilities and stockholders' deficit | ||
| Current liabilities: | ||
| Accounts payable | $11,882 | $14,635 |
| Accrued expenses and other current liabilities | 53,910 | 67,735 |
| Short-term deferred revenue | 695 | — |
| Current portion of long-term debt | — | 17,500 |
| Total current liabilities | 66,487 | 99,870 |
| Deferred revenue, net of current portion | 43,296 | 43,296 |
| Long-term operating lease liabilities | 7,636 | 8,947 |
| Long-term debt, net | 30,145 | 17,183 |
| Liability related to sale of future royalties | 53,498 | 54,013 |
| Refund liability to customer | 39,927 | 40,093 |
| Warrant liability | 4,975 | — |
| Other long-term liabilities | 6,771 | 8,885 |
| Total liabilities | 252,735 | 272,287 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' deficit: | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock $0.00001 par value; 350,000,000 shares authorized at March 31, 2024 and December 31, 2023; 209,454,149 and 194,582,539 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 2 | 2 |
| Additional paid-in capital | 1,599,669 | 1,578,358 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,626,935) | (1,608,950) |
| Total stockholders' deficit | (27,258) | (30,584) |
| Total liabilities and stockholders' deficit | $225,477 | $241,703 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.